Am J Transplant, Volume 16, Suppl 3 Archives - Page 174 of 180 - ATC Abstracts

2016 American Transplant Congress
Some DCD Livers Function as Well as DBD Livers: The Implications of Discarding Usable Livers.
J. Scalea, R. Redfield, D. Foley.
Division of Transplantation, Department of Surgery, University of Wisconsin, Madison, WI.
Background: Multiple single center and national database reports in the liver transplant literature have demonstrated that liver transplantation following donation after circulatory death (DCD) is…
2016 American Transplant Congress
Characteristics and Outcome of Patients Placed on Extracorporeal Membrane Oxygenation as Bridge to Lung Transplantation.
E. Batchelor, J. Bland, D. Douglass, J. Mullins, M. Mohanka, S. Bollineni, V. Kaza, M. Wait, F. Torres, A. Banga.
University of Texas Southwestern Medical Center, Dallas, TX.
BackgroundExtracorporeal membrane oxygenation (ECMO) is increasingly utilized as bridge to lung transplantation (LT), with studies reporting one-year survival of 50-90%. Lower than expected survival has…
2016 American Transplant Congress
Thorough Pre-Transplant Evaluation and Appropriate Case Selection Is the Mainstay for Better Survival in Recipients with Malignancy.
W. Yin.^1,2
¹Surgery, School of Medicine, Tzu Chi University, Hualien, Taiwan; ²Surgery, Dalin Tzu Chi General Hospital, Chia-I, Taiwan.
IntroductionMalignancy has become one of the three major causes of death after transplantation in the past decade and is thus increasingly important in all organ…
2016 American Transplant Congress
Prognosis Value of the Presence and Persistence of C1q Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
E. Bailly,¹ B. Proust,² M. Giral,³ V. Vuiblet,⁴ V. Chatelet,⁵ E. Morelon,⁶ P. Malvezzi,⁷ S. Caillard,⁸ B. Barrou,⁹ L. Couzi,¹⁰ J. Sayegh,¹¹ C. Mousson,¹² D. Anglicheau,¹³ P. Grimbert,¹⁴ M. Hazzan,¹⁵ G. Mourad,¹⁶ R. Purgus,¹⁷ P. Westeel,¹⁸ Y. Lebranchu,^1,19 M. Büchler.^1,19
¹CHU, Tours, France; ²EFS Centre Atlantique, Tours, France; ³ITUN, Nantes, France; ⁴CHU, Reims, France; ⁵CHU, Caen, France; ⁶CHU, Lyon, France; ⁷CHU, Grenoble, France; ⁸CHU, Strasbourg, France; ⁹Hôpital la Pitié Salpêtrière, Paris, France; ¹⁰CHU, Bordeaux, France; ¹¹CHU, Angers, France; ¹²CHU, Dijon, France; ¹³Hôpital Necker, Paris, France; ¹⁴Hôpital Henri Mondor, Paris, France; ¹⁵CHU, Lille, France; ¹⁶CHU, Montpellier, France; ¹⁷CHU, Marseille, France; ¹⁸CHU, Amiens, France; ¹⁹Université F. Rabelais, Tours, France.
Purpose : Longitudinal study of C1q complement fraction binding capacity of donor specific anti-HLA antibodies (DSAs) as a pronostic marker in acute antibody-mediated rejection.Methods :…
2016 American Transplant Congress
Glomerular Capillary C4d Staining without Evidence of Rejection Is Associated with Worse Graft Function in ABO-Incompatible Kidney Transplantation.
D. Toki,¹ M. Inui,¹ M. Okumi,² H. Ishida,² K. Setoguchi,¹ T. Shimizu,² K. Unagami,² K. Tanabe.²
¹Urology, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan; ²Urology, Tokyo Women's Medical University, Tokyo, Japan.
Objectives: C4d staining in the peritubular capillaries (C4d-PTC) is often observed without evidence of rejection in ABO-incompatible kidney transplantation (ABOI-KTx), and this phenomenon is generally…
2016 American Transplant Congress
Plasma Cell Frequency in Renal Rejection After Treatment with Alemtuzumab.
L. Mugge, A. Zimmerman, N. Varshney, A. Gohara, M. Rees, J. Ortiz.
Transplantation, The University of Toledo, Toledo, OH.
Background: The highly successful induction drug Alemtuzumab (Campath) is commonly used prior to renal transplant. Yet, it does not completely ablate plasma cell which, in…
2016 American Transplant Congress
Do All cPRA 100% Candidates Have Equal Access to Organ Allocation?
H. Gebel,^1,2 S. Gustafson,¹ D. Segev,^1,3 B. Kasiske,¹ A. Israni.¹
¹Scientific Registry of Transplant Recipients, Minneapolis; ²Pathology, Emory University Hospital, Atlanta; ³Surgery, Johns Hopkins, Baltimore.
Renal transplant candidates with cPRA values of 98%, 99%, and 100% received local, regional, and national priority, respectively, for deceased donor kidneys with the new…
2016 American Transplant Congress
Managing the Kidney Waiting List: Pride and Prejudice.
F. Smith,¹ C. Sheehan,¹ A. Farney,¹ J. Rogers,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² R. Stratta.¹
¹Surgery, Wake Forest, Winston-Salem, NC; ²Internal Medicine, Wake Forest, Winston-Salem, NC.
Management of the kidney waiting list (WL) is an essential and dynamic aspect of the pretransplant process; however, it remains under-studied and underappreciated. The study…
2016 American Transplant Congress
Ex-Vivo Normothermic Perfusion (EVNP) Attenuation of Kidney Ischemia-Reperfusion Injury (IRI): A Proposed Mechanism.
I. Palma,¹ S. Kabagambe,¹ Y. Smolin,¹ T. Boyer,¹ I. Palma,¹ O. Fiehn,² Y.-J. Chen,¹ J. Sageshima,¹ C. Santhanakrishnan,¹ C. Troppmann,¹ R. Perez.¹
¹Department of Surgery, University of California, Davis Medical Center, Sacramento, CA; ²Department of Molecular and Cellular Biology & Genome Center, University of California-Davis, Davis, CA.
Introduction: EVNP has the potential to repair deceased donor renal IRI. We hypothesize that EVNP may attenuate renal IRI via alteration of lipid metabolism.Methods: Eight…
2016 American Transplant Congress
Short, Cool and Well Oxygenated – HOPE for DCD Kidneys.
P. Kron, A. Schlegel, O. de Rougemont, C. Oberkofler, P.-A. Clavien, P. Dutkowski.
University Hospital, Zurich, Switzerland.
Background Organs from donors after cardiac death (DCD) suffer from severe loss of function requiring development of innovative methods of preservation. A novel perfusion approach,…